E. Romas et al., WEGENER GRANULOMATOSIS - CLINICAL-FEATURES AND PROGNOSIS IN 37 PATIENTS, Australian and New Zealand Journal of Medicine, 23(2), 1993, pp. 168-175
Thirty-seven patients (21 female, 16 male) with Wegener's granulomatos
is (WG) were reviewed. Patients were followed for a mean six years aft
er diagnosis; 14 were followed for more than seven years. The clinical
features were similar to those in previous studies. In this series, o
nly 13 patients (35%) had renal disease at presentation and the cumula
tive incidence of renal involvement was 51%. Thirty-one patients recei
ved treatment which included cyclophosphamide (CP). The case fatality
rate of the six patients not treated with CP was 83% (five deaths). By
contrast, all CP treated patients improved and 21 (68%) had complete
remissions. Nine (29%) were in complete remission for a mean 4.9 years
after discontinuing all treatment. Two were disease free for over ten
years. The actuarial probability of survival for these patients was 9
7% at one year and 71% at ten years. Only three CP treated patients (1
0%) progressed to end-stage renal disease. The case fatality rate was
26% (eight patients) and sepsis was the cause of death in five. Fourte
en patients (45%) treated with CP had at least one relapse of vasculit
is and seven (23%) had multiple (two or more) relapses. These data ind
icate that CP is effective in inducing remissions and prolonging survi
val in patients with WG; however, relapses are frequent.